文献速递介入腹部DSA

减重动脉栓塞的临床安全性:BEAT肥胖试验的初步结果

Clinical Safety of Bariatric Arterial Embolization: Preliminary Results of the BEAT Obesity Trial.
PubMed 文献 · Radiology · 2017-02-14

前瞻性先导试验纳入5例无重要合并症的重度肥胖患者,经导管以300-500μm Embosphere微球栓塞胃底,技术成功率100%,无主要不良事件,2例次要不良事件分别为亚临床胰腺炎和3个月内镜时已愈合的黏膜溃疡;1个月和3个月平均多余体重减少分别为5.9%±2.4和9.0%±4.1,作者认为减重栓塞可行且似乎耐受良好。

要点

  • 栓塞靶血管为胃左动脉(伴或不伴胃网膜动脉),5例技术成功率100%。
  • 主要终点30天不良事件:无主要不良事件,2例次要不良事件为亚临床胰腺炎和已愈合的黏膜溃疡。
  • 1个月和3个月平均多余体重减少分别为5.9%±2.4和9.0%±4.1。

核心结论

  • 减重栓塞在重度肥胖患者中可行且似乎耐受良好;在这一小样本队列中似乎可诱导食欲抑制并可能诱导体重减轻;进一步扩大研究将提供更多关于长期安全性和有效性的信息。

研究设计与样本

  • 机构审查委员会和美国食品药品监督管理局批准的前瞻性医生发起的试验性器械豁免研究,研究阶段自2014年6月2日至2015年8月4日;纳入5例重度肥胖患者(4女1男),年龄31-49岁,平均体重指数43.8 kg/m2±2.9,无临床重要合并症;在透视引导下以300-500μm Embosphere微球行胃底经动脉栓塞;主要终点为30天不良事件,次要终点包括短期体重减轻、血清肥胖相关激素水平、饥饿与饱食评估及生活质量调查(报告至3个月);仅计算集中趋势和变异性的简单统计量,未进行假设检验。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 样本量小(5例)。
  • 作者在结论中指出进一步扩大研究将提供更多关于长期安全性和有效性的信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To conduct a pilot prospective clinical trial to evaluate the feasibility, safety, and short-term efficacy of bariatric embolization, a recently developed endovascular procedure for the treatment of obesity, in patients with severe obesity. Materials and Methods This is an institutional review board- and U.S. Food and Drug Administration-approved prospective physician-initiated investigational device exemption study. This phase of the study ran from June 2, 2014, to August 4, 2015. Five severely obese patients (four women, one man) who were 31-49 years of age and who had a mean body mass index of 43.8 kg/m2 ± 2.9 with no clinically important comorbidities were enrolled in this study. Transarterial embolization of the gastric fundus with fluoroscopic guidance was performed with 300-500-μm Embosphere microspheres. The primary end point was 30-day adverse events (AEs). The secondary end points included short-term weight loss, serum obesity-related hormone levels, hunger and satiety assessments, and quality of life (QOL) surveys, reported up to 3 months. Simple statistics of central tendencies and variability were calculated. No hypothesis testing was performed. Results The left gastric artery, with or without the gastroepiploic artery, was embolized in five patients, with a technical success rate of 100%. There were no major AEs. There were two minor AEs-subclinical pancreatitis and a mucosal ulcer that had healed by the time of 3-month endoscopy. A hospital stay of less than 48 hours for routine supportive care was provided for three patients. Mean excess weight loss of 5.9% ± 2.4 and 9.0% ± 4.1 was noted at 1 month and at 3 months, respectively. Mean change in serum ghrelin was 8.7% ± 34.7 and -17.5% ± 29 at 1 month and 3 months, respectively. Mean changes in serum glucagon-like peptide 1 and peptide YY were 106.6% ± 208.5 and 17.8% ± 54.8 at 1 month. There was a trend toward improvement in QOL parameters. Hunger/appetite scores decreased in the first 2 weeks after the procedure and then rose without reaching preprocedure levels. Conclusion Bariatric embolization is feasible and appears to be well tolerated in severely obese patients. In this small patient cohort, it appears to induce appetite suppression and may induce weight loss. Further expansion of this study will provide more insight into the long-term safety and efficacy of bariatric embolization. © RSNA, 2017 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Weiss CR, Akinwande O, Paudel K, et al. Clinical Safety of Bariatric Arterial Embolization: Preliminary Results of the BEAT Obesity Trial. Radiology. 2017. PMID: 28195823. doi:10.1148/radiol.2016160914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。